Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 111-120 of 236 for multiple myeloma

Edit search filters
  1. First In Human (FIH) Study of REGN5459 in Patients With Relapsed or Refractory Multiple Myeloma (MM)

    Rochester, MN

  2. Assessing Glutamine Metabolism in MGUS and Myeloma

    Rochester, MN

  3. Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ

  4. An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD

    Scottsdale/Phoenix, AZ, Jacksonville, FL

  5. A Study Evaluating the Addition of Venetoclax (ABT-199) to Patients with Multiple Myeloma who are Receiving Bortezomib and Dexamethasone as Standard Therapy

    Rochester, MN

  6. Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma

    Rochester, MN

  7. Lenalidomide and Low-Dose Dexamethasone in Patients with Previously Treated Multiple Myeloma and Kidney Dysfunction

    Scottsdale/Phoenix, AZ, Rochester, MN

  8. Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ

  9. Study to Evaluate Mechanisms of Immunomodulator Sensitivity and Resistance in Multiple Myeloma

    Jacksonville, FL, Rochester, MN, Scottsdale/Phoenix, AZ

  10. Study of ISB 1342, a CD38/​CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

    Rochester, MN

.

Mayo Clinic Footer